Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
Holders of 5% or more of APLS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Apellis Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Wellington Management Group LLP | 13G/A | 10.90%13.8M shares | +3.70 ppfrom 7.20% | Feb 10, 20253 filings | Nov 7, 2025 | SEC |
| BlackRock, Inc. | 13G | 10.50%13.2M shares | +6.00 ppfrom 4.50% | Apr 25, 20252 filings | Feb 6, 2026 | SEC |
| RTW Investments, LP | 13G | 6.10%7.67M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Deep Track Capital, LP | 13G | 5.57%7.00M shares | New | May 16, 20251 filing | May 16, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
11 Schedule 13D and 13G filings on Apellis Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 20264:14 PM ET | Morgan Stanleyand 1 other | 13G/A | 0.00%0 shares | −7.70 ppfrom 7.70%Below 5% | May 31, 2026 | SEC |
| Mar 26, 20263:45 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20268:25 AM ET | RTW Investments, LPand 1 other | 13G | 6.10%7.67M shares | New | Dec 31, 2025 | SEC |
| Feb 6, 202612:08 PM ET | BlackRock, Inc. | 13G | 10.50%13.2M shares | +6.00 ppfrom 4.50% | Jan 31, 2026 | SEC |
| Nov 14, 20253:45 PM ET | EcoR1 Capital, LLCand 2 others | 13G/A | 2.70%3.45M shares | –Below 5% | Sep 30, 2025 | SEC |
| Nov 7, 20258:18 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 10.90%13.8M shares | +3.70 ppfrom 7.20% | Oct 31, 2025 | SEC |
| Aug 12, 202510:34 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 7.20%9.01M shares | −2.30 ppfrom 9.50% | Jun 30, 2025 | SEC |
| May 16, 20254:42 PM ET | Deep Track Capital, LPand 2 others | 13G | 5.57%7.00M shares | New | May 9, 2025 | SEC |
| Apr 25, 20254:14 PM ET | BlackRock, Inc. | 13G/A | 4.50%5.60M shares | –Below 5% | Mar 31, 2025 | SEC |
| Feb 10, 202510:49 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 9.50%11.8M shares | – | Dec 31, 2024 | SEC |
| Feb 3, 20251:09 PM ET | Morgan Stanleyand 1 other | 13G | 7.70%9.59M shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Apellis Pharmaceuticals, Inc. shares.
No Form 144 notices for Apellis Pharmaceuticals, Inc. are on file.